The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CERS | -14.71% | -72.38% | -22.69% | -88% |
| S&P | +18.13% | +110.72% | +16.08% | +776% |
Cerus Corp. engages in the research, development, and manufacturing of biomedical and surgical products. The firm produces blood system for platelets and plasma. It operates through Blood Safety segment. It markets products under the INTERCEPT brand. The company was founded by Laurence M. Corash and John E. Hearst on September 19, 1991 and is headquartered in Concord, CA.
Preliminary third-quarter results pleased the crowd at the company's annual investor meeting.
A better-than-expected outlook after the company's first-quarter report is lifting more than spirits.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $52.45M | 16.3% |
| Gross Profit | $28.98M | 17.5% |
| Gross Margin | 55.25% | 0.5% |
| Market Cap | $269.54M | -17.2% |
| Market Cap / Employee | $0.96M | 0.0% |
| Employees | 281 | -2.4% |
| Net Income | -$5.72M | 1.0% |
| EBITDA | -$10.76M | -22.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $15.99M | 28.9% |
| Accounts Receivable | $31.39M | 32.2% |
| Inventory | 54.5 | 50.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $68.17M | -12.3% |
| Short Term Debt | $30.73M | 46.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -9.47% | 3.0% |
| Return On Invested Capital | -32.41% | 9.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$2.92M | -911.9% |
| Operating Free Cash Flow | -$2.45M | -710.0% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 6.04 | 5.34 | 4.60 | 4.86 | -26.30% |
| Price to Sales | 1.83 | 1.59 | 1.40 | 1.40 | -26.84% |
| Price to Tangible Book Value | 6.19 | 5.48 | 4.71 | 4.97 | -26.52% |
| Price to Free Cash Flow TTM | 33.56 | 38.77 | 78.80 | - | |
| Enterprise Value to EBITDA | -66.65 | -48.42 | -25.03 | -27.07 | -32.71% |
| Free Cash Flow Yield | 3.0% | 2.6% | 1.3% | - | |
| Return on Equity | -38.8% | -38.5% | -36.1% | -36.0% | -24.98% |
| Total Debt | $97.90M | $98.10M | $99.45M | $98.90M | 0.21% |
CERS earnings call for the period ending June 30, 2022.
CERS earnings call for the period ending March 31, 2022.
CERS earnings call for the period ending December 31, 2021.
CERS earnings call for the period ending September 30, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
